Found: 4
Select item for more details and to access through your institution.
Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR).
- Published in:
- British Journal of Dermatology, 2017, v. 177, n. 6, p. 1552, doi. 10.1111/bjd.15722
- By:
- Publication type:
- Article
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
- Published in:
- British Journal of Dermatology, 2011, v. 165, n. 3, p. 661, doi. 10.1111/j.1365-2133.2011.10419.x
- By:
- Publication type:
- Article
U.S. experience of immunomodulators in the treatment of psoriasis: reply from authors.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences.
- Published in:
- British Journal of Dermatology, 2004, v. 151, n. 1, p. 3, doi. 10.1111/j.1365-2133.2004.06009.x
- By:
- Publication type:
- Article